Get started
Author

Tomoya Kagawa

Observed name: TOMOYA KAGAWA
ORCID: 0009-0005-2439-4969
Observed ORCID: 0009-0005-2439-4969
OpenAlex ID: A5113155494
SCO-267, a GPR40 Full Agonist, Stimulates Islet and Gut Hormone Secretion and Improves Glycemic Control in Humans
2021 · Harunobu Nishizaki, Osamu Matsuoka, et al. · Diabetes · 34
PDF
Increases of microRNA let-7e in peripheral blood mononuclear cells in Hashimoto’s disease
2016 · Tomoya Kagawa, Mikio Watanabe, et al. · Endocrine Journal · 27
PDF
Evaluation of the Efficacy and Tolerability of Fixed-Dose Combination Therapy of Azilsartan and Amlodipine Besylate in Japanese Patients With Grade I to II Essential Hypertension
2014 · Hiromi Rakugi, Emi Nakata, et al. · Clinical Therapeutics · 16
Efficacy and Safety of Imarikiren in Patients with Type 2 Diabetes and Microalbuminuria: A Randomized, Controlled Trial
2019 · Sadayoshi Ito, Tomoya Kagawa, et al. · Clinical Journal of the American Society of Nephrology · 7
Effect of TAK ‐085 on Low‐density Lipoprotein Particle Size in Patients with Hypertriglyceridemia: A Double‐blind Randomized Clinical Study
2015 · Ichiro Tatsuno, Kentarou Kudou, et al. · Cardiovascular Therapeutics · 7
PDF
An Exploratory Randomized Trial of SCO-792, an Enteropeptidase Inhibitor, in Patients With Type 2 Diabetes and Albuminuria
2022 · Tomoya Kagawa, Jun Sugama, et al. · Kidney International Reports · 4
PDF
Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Imarikiren, a Novel Renin Inhibitor, in Healthy Male Subjects
2018 · Kumi Matsuno, Shingo Kuroda, et al. · Basic & Clinical Pharmacology & Toxicology · 4
PDF
Efficacy and safety of drospirenone as a progestin‐only pill in Japanese women: A phase III study
2025 · Kunio Kitamura, Enrico Colli, et al. · Journal of obstetrics and gynaecology research · 3
PDF
Oral SSTR5 Antagonist SCO ‐240 for Growth Hormone Stimulation: A Phase I Single‐Dose Study in Healthy Individuals
2024 · Harunobu Nishizaki, Tomoya Kagawa, et al. · Clinical Pharmacology & Therapeutics · 3
PDF
A Randomized, Single‐Center, Double‐Blind, Placebo‐Controlled Multiple‐Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Imarikiren in Healthy Adult Nonelderly and Elderly Male Subjects
2018 · Kumi Matsuno, Shingo Tanaka, et al. · The Journal of Clinical Pharmacology · 3
PDF
Erratum. SCO-267, a GPR40 Full Agonist, Stimulates Islet and Gut Hormone Secretion and Improves Glycemic Control in Humans. Diabetes 2021;70:2364–2376
2021 · Harunobu Nishizaki, Osamu Matsuoka, et al. · Diabetes · 1
PDF
SCO-267, a GPR40 Full Agonist, Stimulates Islet and Gut Hormone Secretion and Improves Glycemic Control in Humans
2021 · Harunobu Nishizaki, Osamu Matsuoka, et al. · 1
Safety and Efficacy of a 24‐Cycle Administration of a Drospirenone‐Only Pill in Japanese Women
2026 · Kunio Kitamura, Enrico Colli, et al. · Journal of obstetrics and gynaecology research
751-P: First-in-Human, Single and Repeated Dose Study of SCO-267, a GPR40 Full Agonist, in Healthy Adults and Subjects with Glucose Intolerance
2021 · HARUNOBU NISHIZAKI, OSAMU MATSUOKA, et al. · Diabetes
Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment
2018 · Yukio Shimasaki, Masashi Sakaki, et al. · Clinical Drug Investigation
PDF
SaO008THE EFFICACY AND SAFETY OF IMARIKIREN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND MICROALBUMINURIA: A RANDOMIZED, MULTI CENTER, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL
2018 · Sadayoshi Ito, Tomoya Kagawa, et al. · Nephrology Dialysis Transplantation
PDF
Works count: 16
Citation count: 110
H-index: 5
I10-index: 3
Year
Topic
Type